Max Zhu

Dr. Max Zhu obtained his Ph.D. at the University of Cambridge in 2013 researching Alzheimer's Disease and is currently finishing the Executive MBA program (2020 Cohort) in the University of Cambridge. He was first a research scientist and Head of Computer-Aided Drug Design at Cantabio in 2015. His areas of responsibility expanded in late 2017 to include business development activities for the company in Asia and became the Head of Business Development in the region. Dr. Zhu has been a key player in the advancement of Cantabio's therapeutic programs and in developing business and investor relationships for the company, where he is able to bring his network of contacts both in research and the investment community to help with the commercial development of the company. He has become the Chief Business Development Officer at Cantabio from 2019 to 2021.

Dr. Zhu's Ph.D. thesis focused on computational studies of beta-amyloid peptides and amyloid in Alzheimer's disease. This work has led to the discovery of a set of potential drug leads for Alzheimer's disease. Dr. Zhu's research required the use of computer science, AI, genome and protein structure analysis, computational biology and chemistry, applying the combination of different skillsets and knowledge in a multi-disciplinary biomedical research environment, and he has been both lead and co-author on a number of peer-reviewed articles in this area. Prior to working at Cantabio, Dr. Zhu has taken up R&D and business development roles in multiple biotech companies. In these roles, he developed expertise and know-how in biomedical innovations and R&D commercialization, as well as strategies, sales and marketing, gaining valuable experiences as a biotech entrepreneur in the greater China area.